Aurelie Auguste
Villejuif, 94805, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors.
Journal: Cell reports. Medicine
Published: November 16, 2023
Combined Tumor-Based BRCA1/2 and TP53 Mutation Testing in Ovarian Cancer.
Journal: International journal of molecular sciences
Published: March 13, 2023
Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
Journal: Virchows Archiv : an international journal of pathology
Published: May 25, 2020
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial.
Journal: JTO clinical and research reports
Published: April 04, 2020
Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer.
Journal: Cancers
Published: February 24, 2020
Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
Journal: British journal of cancer
Published: July 05, 2019
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 11, 2018
[Erratum to: "Histological and molecular classification of endometrial carcinoma and therapeutical implications" [Bull. Cancer 104 (2017) 1001-1012]].
Journal: Bulletin du cancer
Published: February 04, 2018
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Published: August 01, 2017
Histological and molecular classification of endometrial carcinoma and therapeutical implications
Journal: Bulletin du cancer
Published: July 26, 2017
Last Updated: 09/26/2026